New molecular formats are gaining momentum in today’s market. They are extremely diverse and can often encompass multiple chains and multiple domains, which presents unique challenges during process development and manufacture. Included in these more complex product types are fragment antigen-binding (Fab) and Fc-Fusion proteins. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center